|
| 37444449 | Presenting Symptoms in Newly Diagnosed Myeloma, Relation to Organ Damage, and Implications for Symptom-Directed Screening: A Secondary Analysis from the Tackling Early Morbidity and Mortality in Myeloma (TEAMM) Trial. | Cancers (Basel) | 2023 |
| 34848027 | Re: The potential of abbreviated breast MRI (FAST MRI) as a tool for breast cancer screening: a systematic review and meta-analysis. A reply. | Clin Radiol | 2022 |
| 35790108 | Clinical characteristics and outcomes of IgD myeloma: experience across UK national trials. | Blood Adv | 2022 |
| 35525376 | Prognostic stratification of HPV-associated oropharyngeal cancer based on CD103<sup>+</sup> immune cell abundance in patients treated on TROG 12.01 and De-ESCALaTE randomized trials. | Ann Oncol | 2022 |
| 36446771 | Bortezomib, Bendamustine and Dexamethasone vs Thalidomide, Bendamustine and Dexamethasone in Myeloma patients presenting with renal failure (OPTIMAL): a randomised, multi-centre phase II trial. | Blood Cancer J | 2022 |
| 34875674 | Multi-omic machine learning predictor of breast cancer therapy response. | Nature | 2022 |
| 34902335 | Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. | Lancet Oncol | 2022 |
| 32723485 | Optimising the Duration of Adjuvant Trastuzumab in Early Breast Cancer in the UK. | Clin Oncol (R Coll Radiol) | 2021 |
| 33715828 | Commentary on: Introduction of an abbreviated breast MRI service in the UK as part of the BRAID trial: practicalities, challenges, and future directions. | Clin Radiol | 2021 |
| 34519274 | Low serum 1,25(OH)2D3 in end-stage renal disease: is reduced 1α-hydroxylase the only problem? | Endocr Connect | 2021 |
| 34418219 | Development and validation of an improved classification and risk stratification system for carotid body tumors: Multinational collaborative cohort study. | Head Neck | 2021 |
| 34238931 | Comparative survival analysis of multiparametric tests-when molecular tests disagree-A TEAM Pathology study. | NPJ Breast Cancer | 2021 |
| 34340917 | Improvement in Dysphagia Outcomes Following Clinical Target Volume Reduction in the De-ESCALaTE Study. | Clin Oncol (R Coll Radiol) | 2021 |
| 33025481 | A multicentre prospective feasibility study of carbon dye tattooing of biopsied axillary node and surgical localisation in breast cancer patients. | Breast Cancer Res Treat | 2021 |
| 33321287 | Hypofractionated chemoradiation for head and cancer: Data from the PET NECK trial. | Oral Oncol | 2021 |
| 32798327 | Diagnostic pathways in multiple myeloma and their relationship to end organ damage: an analysis from the Tackling Early Morbidity and Mortality in Myeloma (TEAMM) trial. | Br J Haematol | 2021 |
| 32880572 | Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT. | Health Technol Assess | 2020 |
| 32089356 | Strategies to Improve Recruitment to a De-escalation Trial: A Mixed-Methods Study of the OPTIMA Prelim Trial in Early Breast Cancer. | Clin Oncol (R Coll Radiol) | 2020 |
| 32061290 | Protective strategies to prevent trastuzumab-induced cardiotoxicity - Authors' reply. | Lancet | 2020 |
| 31785830 | Synchronous versus sequential chemo-radiotherapy in patients with early stage breast cancer (SECRAB): A randomised, phase III, trial. | Radiother Oncol | 2020 |
| 31995662 | Treatment of cancer-associated venous thromboembolism: 12-month outcomes of the placebo versus rivaroxaban randomization of the SELECT-D Trial (SELECT-D: 12m). | J Thromb Haemost | 2020 |
| 31949161 | A network analysis to identify mediators of germline-driven differences in breast cancer prognosis. | Nat Commun | 2020 |
| 32007200 | Levofloxacin prophylaxis in patients with myeloma - Authors' reply. | Lancet Oncol | 2020 |
| 31794928 | Concurrent cisplatin or cetuximab with radiotherapy for HPV-positive oropharyngeal cancer: Medical resource use, costs, and quality-adjusted survival from the De-ESCALaTE HPV trial. | Eur J Cancer | 2020 |
| 33078998 | Comparison of Whole-Body MRI, CT, and Bone Scintigraphy for Response Evaluation of Cancer Therapeutics in Metastatic Breast Cancer to Bone. | Radiology | 2020 |
| 33149136 | Anti-bacterial antibodies in multiple myeloma patients at disease presentation, in response to therapy and in remission: implications for patient management. | Blood Cancer J | 2020 |
| 32881987 | Computational approaches to support comparative analysis of multiparametric tests: Modelling versus Training. | PLoS One | 2020 |
| 30449623 | Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. | Lancet | 2019 |
| 31668592 | Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial. | Lancet Oncol | 2019 |
| 31690402 | Prophylactic levofloxacin to prevent infections in newly diagnosed symptomatic myeloma: the TEAMM RCT. | Health Technol Assess | 2019 |
| 31559859 | Can mammogram readers swiftly and effectively learn to interpret first post-contrast acquisition subtracted (FAST) MRI, a type of abbreviated breast MRI?: a single centre data-interpretation study. | Br J Radiol | 2019 |
| 31430371 | Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial. | Ann Oncol | 2019 |
| 30654104 | Low serum 25-hydroxyvitamin D is associated with increased bladder cancer risk: A systematic review and evidence of a potential mechanism. | J Steroid Biochem Mol Biol | 2019 |
| 29112704 | Circulating tumor DNA predicts survival in patients with resected high-risk stage II/III melanoma. | Ann Oncol | 2018 |
| 30220318 | The impact of institutional clinical trial recruitment versus hospital volume on survival outcomes of patients with head and neck cancer: An analysis of the PET-NECK trial outcomes, UKCRN portfolio, and Hospital Episode Statistics (HES) in England. | Oral Oncol | 2018 |
| 29925902 | Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials. | Leukemia | 2018 |
| 30033445 | 25-hydroxyvitamin D serum levels in patients with high risk resected melanoma treated in an adjuvant bevacizumab trial. | Br J Cancer | 2018 |
| 30057084 | Considerations for a head and neck smoking cessation support programme; A qualitative study of the challenges in quitting smoking after treatment for head and neck cancer. | Eur J Oncol Nurs | 2018 |
| 29634439 | Double Reading in Breast Cancer Screening: Cohort Evaluation in the CO-OPS Trial. | Radiology | 2018 |
| 29746227 | Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). | J Clin Oncol | 2018 |
| 29621991 | Adjuvant trastuzumab duration trials in HER2 positive breast cancer - what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results. | BMC Cancer | 2018 |
| 28548129 | Central pathology review with two-stage quality assurance for pathological response after neoadjuvant chemotherapy in the ARTemis Trial. | Mod Pathol | 2017 |
| 28459938 | Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial. | Ann Oncol | 2017 |
| 28409743 | PET-NECK: a multicentre randomised Phase III non-inferiority trial comparing a positron emission tomography-computerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2/N3) nodal metastases in patients with squamous cell head and neck cancer. | Health Technol Assess | 2017 |
| 28222072 | Discrepancies in central review re-testing of patients with ER-positive and HER2-negative breast cancer in the OPTIMA prelim randomised clinical trial. | Br J Cancer | 2017 |
| 28479233 | Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial. | Lancet Oncol | 2017 |
| 29241890 | Value of Information Analysis of Multiparameter Tests for Chemotherapy in Early Breast Cancer: The OPTIMA Prelim Trial. | Value Health | 2017 |
| 28881249 | Cost-effectiveness analysis of PET-CT-guided management for locally advanced head and neck cancer. | Eur J Cancer | 2017 |
| 28720094 | A literature review of applied adaptive design methodology within the field of oncology in randomised controlled trials and a proposed extension to the CONSORT guidelines. | BMC Med Res Methodol | 2017 |
| 28525534 | Lymphocyte density determined by computational pathology validated as a predictor of response to neoadjuvant chemotherapy in breast cancer: secondary analysis of the ARTemis trial. | Ann Oncol | 2017 |